Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: A meta-analysis

Trinh Trung Hieu, Anthony W Russell, Ross Cuneo, Justin Clark, Tomas Kron, Per Hall, Suhail A R Doi

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

Radioiodine-131 ((131)I) is widely used for diagnosis and treatment of benign thyroid diseases. Observational studies have not been conclusive about the carcinogenic potential of (131)I and we therefore conducted a meta-analysis. We performed a literature search till September 2011 which included (131)I as a diagnostic or treatment modality ((131)I for treatment of thyroid cancer was excluded). Data on 64 different organ or organ group subsets comprising 22 029 exposed subjects in the therapeutic cohorts and 24 799 in the diagnostic cohorts in seven studies were included. Outcome was pooled as the relative risk (RR) using both standard and bias adjusted methods. Quality assessment was performed using a study-specific instrument. No increase in overall (RR 1.06, 95% CI: 0.94-1.19), main organ group or combined organ group (four groups known to concentrate (131)I; RR 1.11, 95% CI: 0.94-1.31) risks was demonstrable. Individual organs demonstrated a higher risk for kidney (RR 1.70, 95% CI: 1.15-2.51) and thyroid (RR 1.99, 95% CI: 1.22-3.26) cancers with a strong trend for stomach cancer (RR 1.11, 95% CI: 0.92-1.33). A thyroid dose effect was seen for diagnostic doses. While there is no increase in the overall burden of cancer, an increase in risk to a few organs is seen which requires substantiation. The possible increase in thyroid cancer risk following diagnostic (131)I use should no longer be of concern given that it has effectively been replaced by the use of 99mTc-pertechnetate.

Original languageEnglish
Pages (from-to)645-55
Number of pages11
JournalEndocrine-Related Cancer
Volume19
Issue number5
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Fingerprint

Thyroid Diseases
Iodine
Meta-Analysis
Neoplasms
Thyroid Neoplasms
Thyroid Gland
Sodium Pertechnetate Tc 99m
Stomach Neoplasms
Observational Studies
Kidney

Cite this

Hieu, T. T., Russell, A. W., Cuneo, R., Clark, J., Kron, T., Hall, P., & Doi, S. A. R. (2012). Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: A meta-analysis. Endocrine-Related Cancer, 19(5), 645-55. https://doi.org/10.1530/ERC-12-0176
Hieu, Trinh Trung ; Russell, Anthony W ; Cuneo, Ross ; Clark, Justin ; Kron, Tomas ; Hall, Per ; Doi, Suhail A R. / Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases : A meta-analysis. In: Endocrine-Related Cancer. 2012 ; Vol. 19, No. 5. pp. 645-55.
@article{5aeda3a72d1e4127a84fd06ab9f1cfba,
title = "Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: A meta-analysis",
abstract = "Radioiodine-131 ((131)I) is widely used for diagnosis and treatment of benign thyroid diseases. Observational studies have not been conclusive about the carcinogenic potential of (131)I and we therefore conducted a meta-analysis. We performed a literature search till September 2011 which included (131)I as a diagnostic or treatment modality ((131)I for treatment of thyroid cancer was excluded). Data on 64 different organ or organ group subsets comprising 22 029 exposed subjects in the therapeutic cohorts and 24 799 in the diagnostic cohorts in seven studies were included. Outcome was pooled as the relative risk (RR) using both standard and bias adjusted methods. Quality assessment was performed using a study-specific instrument. No increase in overall (RR 1.06, 95{\%} CI: 0.94-1.19), main organ group or combined organ group (four groups known to concentrate (131)I; RR 1.11, 95{\%} CI: 0.94-1.31) risks was demonstrable. Individual organs demonstrated a higher risk for kidney (RR 1.70, 95{\%} CI: 1.15-2.51) and thyroid (RR 1.99, 95{\%} CI: 1.22-3.26) cancers with a strong trend for stomach cancer (RR 1.11, 95{\%} CI: 0.92-1.33). A thyroid dose effect was seen for diagnostic doses. While there is no increase in the overall burden of cancer, an increase in risk to a few organs is seen which requires substantiation. The possible increase in thyroid cancer risk following diagnostic (131)I use should no longer be of concern given that it has effectively been replaced by the use of 99mTc-pertechnetate.",
author = "Hieu, {Trinh Trung} and Russell, {Anthony W} and Ross Cuneo and Justin Clark and Tomas Kron and Per Hall and Doi, {Suhail A R}",
year = "2012",
month = "10",
doi = "10.1530/ERC-12-0176",
language = "English",
volume = "19",
pages = "645--55",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "5",

}

Hieu, TT, Russell, AW, Cuneo, R, Clark, J, Kron, T, Hall, P & Doi, SAR 2012, 'Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: A meta-analysis' Endocrine-Related Cancer, vol. 19, no. 5, pp. 645-55. https://doi.org/10.1530/ERC-12-0176

Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases : A meta-analysis. / Hieu, Trinh Trung; Russell, Anthony W; Cuneo, Ross; Clark, Justin; Kron, Tomas; Hall, Per; Doi, Suhail A R.

In: Endocrine-Related Cancer, Vol. 19, No. 5, 10.2012, p. 645-55.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases

T2 - A meta-analysis

AU - Hieu, Trinh Trung

AU - Russell, Anthony W

AU - Cuneo, Ross

AU - Clark, Justin

AU - Kron, Tomas

AU - Hall, Per

AU - Doi, Suhail A R

PY - 2012/10

Y1 - 2012/10

N2 - Radioiodine-131 ((131)I) is widely used for diagnosis and treatment of benign thyroid diseases. Observational studies have not been conclusive about the carcinogenic potential of (131)I and we therefore conducted a meta-analysis. We performed a literature search till September 2011 which included (131)I as a diagnostic or treatment modality ((131)I for treatment of thyroid cancer was excluded). Data on 64 different organ or organ group subsets comprising 22 029 exposed subjects in the therapeutic cohorts and 24 799 in the diagnostic cohorts in seven studies were included. Outcome was pooled as the relative risk (RR) using both standard and bias adjusted methods. Quality assessment was performed using a study-specific instrument. No increase in overall (RR 1.06, 95% CI: 0.94-1.19), main organ group or combined organ group (four groups known to concentrate (131)I; RR 1.11, 95% CI: 0.94-1.31) risks was demonstrable. Individual organs demonstrated a higher risk for kidney (RR 1.70, 95% CI: 1.15-2.51) and thyroid (RR 1.99, 95% CI: 1.22-3.26) cancers with a strong trend for stomach cancer (RR 1.11, 95% CI: 0.92-1.33). A thyroid dose effect was seen for diagnostic doses. While there is no increase in the overall burden of cancer, an increase in risk to a few organs is seen which requires substantiation. The possible increase in thyroid cancer risk following diagnostic (131)I use should no longer be of concern given that it has effectively been replaced by the use of 99mTc-pertechnetate.

AB - Radioiodine-131 ((131)I) is widely used for diagnosis and treatment of benign thyroid diseases. Observational studies have not been conclusive about the carcinogenic potential of (131)I and we therefore conducted a meta-analysis. We performed a literature search till September 2011 which included (131)I as a diagnostic or treatment modality ((131)I for treatment of thyroid cancer was excluded). Data on 64 different organ or organ group subsets comprising 22 029 exposed subjects in the therapeutic cohorts and 24 799 in the diagnostic cohorts in seven studies were included. Outcome was pooled as the relative risk (RR) using both standard and bias adjusted methods. Quality assessment was performed using a study-specific instrument. No increase in overall (RR 1.06, 95% CI: 0.94-1.19), main organ group or combined organ group (four groups known to concentrate (131)I; RR 1.11, 95% CI: 0.94-1.31) risks was demonstrable. Individual organs demonstrated a higher risk for kidney (RR 1.70, 95% CI: 1.15-2.51) and thyroid (RR 1.99, 95% CI: 1.22-3.26) cancers with a strong trend for stomach cancer (RR 1.11, 95% CI: 0.92-1.33). A thyroid dose effect was seen for diagnostic doses. While there is no increase in the overall burden of cancer, an increase in risk to a few organs is seen which requires substantiation. The possible increase in thyroid cancer risk following diagnostic (131)I use should no longer be of concern given that it has effectively been replaced by the use of 99mTc-pertechnetate.

U2 - 10.1530/ERC-12-0176

DO - 10.1530/ERC-12-0176

M3 - Article

VL - 19

SP - 645

EP - 655

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 5

ER -